PRAMOMOLECULAR is financially supported by the European Union from The Operational Program EFRE Berlin 2027 and by the State of Berlin.

Within the scope of the project funding, we intend to provide disease-specific drug candidates to address overexpressed or mutated RAS proteins. Misregulated RAS proteins can lead to severe metabolic diseases or cancer. We initially want to address KRAS-dependent cancers, one of the most common RAS mutations, which can lead to non-small cell lung cancer, pancreatic adenocarcinoma or melanoma.

As part of the funded project, we intend to provide disease-specific in vivo proof of principle in a mouse PDX model, by downregulating the overexpressed/ mutated KRAS protein. With the help of a self-delivering siRNA, based on our proprietary platform technology, the growth of metastases or a tumor should be inhibited by local, intraperitoneal or systemic application against the mutated KRAS oncoprotein. We expect a significant therapeutic effects by reduction of tumor growth.